Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
6/8/2026, 12:00:00 AM
The U.S. Food and Drug Administration (FDA) approved an expanded indication for Hympavzi (marstacimab-hncq) for the treatment of patients with hemophilia A or B, including pediatric patients and those with inhibitors, on June 8, 2026. Medium importance estimated as expanded FDA approval typically increases the addressable patient population and revenue.
Korean Translation
2026년 6월 8일, 미국 식품의약국(FDA)이 소아 및 억제인자 보유 환자를 포함한 A형 또는 B형 혈우병 환자 치료를 위한 힘파브지(Hympavzi)의 적응증 확대를 승인함. 적응증 확대에 따른 매출 증대 가능성으로 중간 중요도로 예상됨.
Related Recent Events
Synopsys Inc (SNPS) · Other
An investor day to discuss long-term financial targets and strategy is scheduled.
9/30/2026, 12:00:00 AM
Broadcom Inc (AVGO) · Earnings Release
Broadcom's Q3 2026 earnings release on September 3, 2026. This event is expected to have a medium impact as it will provide critical updates on AI revenue growth, scheduled
9/3/2026, 12:00:00 AM
NetApp Inc (NTAP) · Earnings Release
Next quarterly earnings for Q1 fiscal year 2027 are scheduled.
8/26/2026, 12:00:00 AM
HEICO Corp (HEI) · Earnings Release
Next quarterly earnings for Q3 2026 are scheduled to be reported on 2026-08-24, with analysts forecasting an EPS of $1.46; low importance is estimated as market impact is typically limited for scheduled announcements, scheduled.
8/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart is scheduled to release its Q2 FY2027 earnings results on 2026-08-20, scheduled. Medium importance is estimated as earnings releases typically trigger significant market volatility.
8/20/2026, 12:00:00 AM
Microsoft Corp (MSFT) · Other
Microsoft declared a quarterly dividend of $0.91 per share with an ex-dividend date of August 20, 2026, scheduled.
8/20/2026, 12:00:00 AM